186 related articles for article (PubMed ID: 33128167)
1. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis.
Lei L; Wang Y; Zheng YW; Fei LR; Shen HY; Li ZH; Huang WJ; Yu JH; Xu HT
Curr Cancer Drug Targets; 2019; 19(8):674-680. PubMed ID: 30451112
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
Niu L; Gao Z; Cui Y; Yang X; Li H
Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
[TBL] [Abstract][Full Text] [Related]
5. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
[TBL] [Abstract][Full Text] [Related]
6. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
[TBL] [Abstract][Full Text] [Related]
8. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U
Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736
[TBL] [Abstract][Full Text] [Related]
9. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
10. ING5 inhibits lung cancer invasion and epithelial-mesenchymal transition by inhibiting the WNT/β-catenin pathway.
Liu XL; Meng J; Zhang XT; Liang XH; Zhang F; Zhao GR; Zhang T
Thorac Cancer; 2019 Apr; 10(4):848-855. PubMed ID: 30810286
[TBL] [Abstract][Full Text] [Related]
11. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
[TBL] [Abstract][Full Text] [Related]
12. SOX9 drives the epithelial-mesenchymal transition in non-small-cell lung cancer through the Wnt/β-catenin pathway.
Huang JQ; Wei FK; Xu XL; Ye SX; Song JW; Ding PK; Zhu J; Li HF; Luo XP; Gong H; Su L; Yang L; Gong LY
J Transl Med; 2019 May; 17(1):143. PubMed ID: 31060551
[TBL] [Abstract][Full Text] [Related]
13. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
15. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
Cai W; Ni W; Jin Y; Li Y
Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway by targeting CUL4B in pancreatic cancer cells.
Zhang JQ; Chen S; Gu JN; Zhu Y; Zhan Q; Cheng DF; Chen H; Deng XX; Shen BY; Peng CH
J Cell Biochem; 2018 Jan; 119(1):1027-1040. PubMed ID: 28685847
[TBL] [Abstract][Full Text] [Related]
17. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
Zhou XY; Shu XM
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
[TBL] [Abstract][Full Text] [Related]
18. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
19. CUL4B promotes metastasis and proliferation in pancreatic cancer cells by inducing epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.
He YM; Xiao YS; Wei L; Zhang JQ; Peng CH
J Cell Biochem; 2018 Jul; 119(7):5308-5323. PubMed ID: 29274277
[TBL] [Abstract][Full Text] [Related]
20. DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
Yang MQ; Bai LL; Lei L; Zheng YW; Wang Z; Li ZH; Liu CC; Huang WJ; Xu HT
Oncol Rep; 2020 Apr; 43(4):1338-1348. PubMed ID: 32020224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
